CTKB CYTEK BIOSCIENCES INC revenue, earnings and financials
For the quarter ended June 30, 2026, CYTEK BIOSCIENCES INC reported revenue of $48.1M (up 5.6% from a year earlier), net income of −$12.2M and diluted EPS of n/a; over the last four quarters revenue was $207M and net income −$80.6M; for the fiscal year ended December 2025 revenue was $201M, up 0.5% on the year before.
CTKB annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $201M, gross profit $104M, operating income −$40.4M, net income −$66.5M (margin -33.0%), EPS n/a
- Fiscal year ended Dec 2024: revenue $200M, gross profit $111M, operating income −$20.5M, net income −$6.02M (margin -3.0%), EPS n/a
- Fiscal year ended Dec 2023: revenue $193M, gross profit $109M, operating income −$27.8M, net income −$12.1M (margin -6.3%), EPS −$0.09
- Fiscal year ended Dec 2022: revenue $2.96M, gross profit $101M, operating income −$1.80M, net income $2.48M (margin 83.8%), EPS $0.02
- Fiscal year ended Dec 2021: revenue $2.18M, gross profit $79.1M, operating income $9.16M, net income $3.03M (margin 138.8%), EPS $0.00
CTKB quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $48.1M (up 5.6% year over year), net income −$12.2M, EPS n/a
- Quarter ended Mar 31, 2026: revenue $44.1M (up 6.5% year over year), net income −$18.9M, EPS n/a
- Quarter ended Dec 31, 2025 (from the annual report): revenue $62.1M (up 8.1% year over year), net income −$44.1M, EPS n/a
- Quarter ended Sep 30, 2025: revenue $52.3M (up 1.5% year over year), net income −$5.48M, EPS n/a
- Quarter ended Jun 30, 2025: revenue $45.6M (down 2.2% year over year), net income −$5.58M, EPS n/a
- Quarter ended Mar 31, 2025: revenue $41.5M (down 7.6% year over year), net income −$11.4M, EPS n/a
- Quarter ended Dec 31, 2024 (from the annual report): revenue $57.5M (down 1.3% year over year), net income $9.64M, EPS n/a
- Quarter ended Sep 30, 2024: revenue $51.5M (up 7.3% year over year), net income $941K, EPS n/a
- Quarter ended Jun 30, 2024: revenue $46.6M (down 6.2% year over year), net income −$10.4M, EPS n/a
- Quarter ended Mar 31, 2024: revenue $44.9M (up 21.0% year over year), net income −$6.17M, EPS n/a
- Quarter ended Dec 31, 2023 (from the annual report): revenue $58.2M (up 151.7% year over year), net income $5.50M, EPS n/a
- Quarter ended Sep 30, 2023: revenue $48.0M (up 18.6% year over year), net income −$6.46M, EPS n/a
- Quarter ended Jun 30, 2023: revenue $49.7M (up 23.7% year over year), net income −$4.39M, EPS n/a
- Quarter ended Mar 31, 2023: revenue $37.1M (up 5.8% year over year), net income −$6.81M, EPS n/a
- Quarter ended Dec 31, 2022 (from the annual report): revenue −$113M (down 29.8% year over year), net income $3.72M, EPS $0.01
- Quarter ended Sep 30, 2022: revenue $40.5M (up 17.7% year over year), net income $1.63M, EPS −$0.01
- Quarter ended Jun 30, 2022: revenue $40.2M (up 32.1% year over year), net income −$702K, EPS $0.00
- Quarter ended Mar 31, 2022: revenue $35.1M (up 44.5% year over year), net income −$2.16M, EPS $0.02
- Quarter ended Dec 31, 2021 (from the annual report): revenue −$86.9M, net income −$1.17M, EPS $0.00
- Quarter ended Sep 30, 2021: revenue $34.4M, net income $1.42M, EPS $0.00
CTKB cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$4.69M, share buybacks $15.1M
- Fiscal year ended Dec 2024: operating cash flow $25.4M, share buybacks $21.6M
- Fiscal year ended Dec 2023: operating cash flow $5.28M, share buybacks $44.2M
- Fiscal year ended Dec 2022: operating cash flow −$12.2M, share buybacks $0
- Fiscal year ended Dec 2021: operating cash flow $4.63M, share buybacks $0
CTKB balance sheet
- Jun 30, 2026: cash $73.8M, total assets $447M, total liabilities $125M, shareholders' equity $322M
- Mar 31, 2026: cash $65.7M, total assets $449M, total liabilities $121M, shareholders' equity $328M
- Dec 31, 2025: cash $90.9M, total assets $462M, total liabilities $120M, shareholders' equity $342M
- Sep 30, 2025: cash $93.3M, total assets $495M, total liabilities $116M, shareholders' equity $379M
- Jun 30, 2025: cash $75.5M, total assets $493M, total liabilities $116M, shareholders' equity $378M
- Mar 31, 2025: cash $95.3M, total assets $483M, total liabilities $103M, shareholders' equity $380M
- Dec 31, 2024: cash $98.7M, total assets $500M, total liabilities $104M, shareholders' equity $396M
- Sep 30, 2024: cash $162M, total assets $491M, total liabilities $106M, shareholders' equity $385M
What is CTKB's revenue?
CYTEK BIOSCIENCES INC reported $207M of revenue over its last four quarters, through June 30, 2026.
Is CTKB profitable?
No. CYTEK BIOSCIENCES INC lost $80.6M over the last four quarters.